Find safe dose for Parkinson
- Trial ID
- NCT06189170
- Official Title
- A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
- Goal
- Find safe dose for Parkinson
- Phase
- EARLY_PHASE1
- Status
- RECRUITING
- Sponsor
- Kariya Pharmaceuticals
- Study Type
- INTERVENTIONAL
- Enrollment
- 88 participants
- Conditions
- Safety Issues, Tolerance
- Interventions
- KP405, Placebo
Summary For Families
The trial is aiming to establish whether KP405 is safe and well tolerated, and to find appropriate dose ranges before any larger Parkinson's studies. Participants receive single and then multiple escalating doses of KP405 or placebo, so researchers can track how the drug is handled by the body, what side effects appear, and whether it is tolerated alongside usual Parkinson's care such as levodopa. Adults aged 18 to 80 are being recruited, including healthy volunteers and people with Parkinson's who meet UK Brain Bank criteria, while people with other significant neurological or unstable medical conditions are excluded.
Locations
- MAC, Manchester, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying KP405. The trial is aiming to establish whether KP405 is safe and well tolerated, and to find appropriate dose ranges before any larger Parkinson's studies. Participants receive single and then multiple escalating doses of KP405 or placebo, so researchers can track how the drug is handled by the body, what side effects appear, and whether it is tolerated alongside usual Parkinson's care such as levodopa. Adults aged 18 to 80 are being recruited, including healthy volunteers and people with Parkinson's who meet UK Brain Bank criteria, while people with other significant neurological or unstable medical conditions are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 1 year and 5 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.